3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 8.70 points (-0.1%) at 17,070 as of Thursday, Sept. 4, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,021 issues advancing vs. 2,057 declining with 126 unchanged.

The Drugs industry as a whole closed the day down 1.0% versus the S&P 500, which was down 0.2%. Top gainers within the Drugs industry included Reliv' International ( RELV), up 1.6%, Celator Pharmaceuticals ( CPXX), up 3.8%, Fate Therapeutics ( FATE), up 2.9%, Novogen ( NVGN), up 2.1% and SCYNEXIS ( SCYX), up 6.3%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Fate Therapeutics ( FATE) is one of the companies that pushed the Drugs industry higher today. Fate Therapeutics was up $0.15 (2.9%) to $5.39 on light volume. Throughout the day, 1,702 shares of Fate Therapeutics exchanged hands as compared to its average daily volume of 19,400 shares. The stock ranged in a price between $5.24-$5.41 after having opened the day at $5.29 as compared to the previous trading day's close of $5.24.

Fate Therapeutics has a market cap of $108.0 million and is part of the health care sector. Shares are down 16.4% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Celator Pharmaceuticals ( CPXX) was up $0.10 (3.8%) to $2.74 on light volume. Throughout the day, 7,505 shares of Celator Pharmaceuticals exchanged hands as compared to its average daily volume of 33,600 shares. The stock ranged in a price between $2.64-$2.77 after having opened the day at $2.72 as compared to the previous trading day's close of $2.64.

Celator Pharmaceuticals has a market cap of $69.6 million and is part of the health care sector. Shares are down 18.8% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Reliv' International ( RELV) was another company that pushed the Drugs industry higher today. Reliv' International was up $0.02 (1.6%) to $1.26 on light volume. Throughout the day, 12,081 shares of Reliv' International exchanged hands as compared to its average daily volume of 39,700 shares. The stock ranged in a price between $1.21-$1.30 after having opened the day at $1.24 as compared to the previous trading day's close of $1.24.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $15.5 million and is part of the health care sector. Shares are down 55.9% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • Although RELV's debt-to-equity ratio of 0.22 is very low, it is currently higher than that of the industry average. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.75 is somewhat weak and could be cause for future problems.
  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 79.27%. Regardless of RELV's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, RELV's net profit margin of -1.99% significantly underperformed when compared to the industry average.
  • RELV's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 49.35%, which is also worse than the performance of the S&P 500 Index. Despite the heavy decline in its share price, this stock is still more expensive (when compared to its current earnings) than most other companies in its industry.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Personal Products industry and the overall market, RELIV INTERNATIONAL INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices